232 related articles for article (PubMed ID: 18246318)
1. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV; Zheng J; Jablonski EM; Galbaugh TL; Fang F
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):147-56. PubMed ID: 18246318
[TBL] [Abstract][Full Text] [Related]
2. The role of prolactin and growth hormone in breast cancer.
Wennbo H; Törnell J
Oncogene; 2000 Feb; 19(8):1072-6. PubMed ID: 10713692
[TBL] [Abstract][Full Text] [Related]
3. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
4. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications.
Goffin V; Touraine P
Expert Opin Ther Targets; 2015; 19(9):1229-44. PubMed ID: 26063597
[TBL] [Abstract][Full Text] [Related]
5. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano JS; Rendahl KG; Karim C; Embry MG; Ghoddusi M; Holash J; Fanidi A; Abrams TJ; Abraham JA
Mol Cancer Ther; 2013 Mar; 12(3):295-305. PubMed ID: 23270929
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
10. [Prolactin and serotonin].
Lychkovq AE; Puzikov AM
Vestn Ross Akad Med Nauk; 2014; (1-2):38-45. PubMed ID: 25055559
[TBL] [Abstract][Full Text] [Related]
11. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
12. Regulation of prolactin receptor levels and activity in breast cancer.
Swaminathan G; Varghese B; Fuchs SY
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):81-91. PubMed ID: 18204982
[TBL] [Abstract][Full Text] [Related]
13. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
14. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
15. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme.
Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Abt A; Orrillo SJ; Lastra Y; De Simone E; Boutillon F; Goffin V; Seilicovich A; Pisera DA; Ferraris MJ; Candolfi M
Sci Rep; 2019 Dec; 9(1):19578. PubMed ID: 31862900
[TBL] [Abstract][Full Text] [Related]
16. Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
Thomas LN; Chedrawe ER; Barnes PJ; Too CKL
Breast Cancer Res Treat; 2017 Jul; 164(1):27-40. PubMed ID: 28364216
[TBL] [Abstract][Full Text] [Related]
17. Development of new prolactin analogs acting as pure prolactin receptor antagonists.
Goffin V; Bernichtein S; Kayser C; Kelly PA
Pituitary; 2003 Sep; 6(2):89-95. PubMed ID: 14703018
[TBL] [Abstract][Full Text] [Related]
18. Association of prolactin and its receptor gene regions with familial breast cancer.
Vaclavicek A; Hemminki K; Bartram CR; Wagner K; Wappenschmidt B; Meindl A; Schmutzler RK; Klaes R; Untch M; Burwinkel B; Försti A
J Clin Endocrinol Metab; 2006 Apr; 91(4):1513-9. PubMed ID: 16434456
[TBL] [Abstract][Full Text] [Related]
19. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer and Prolactin - New Mechanisms and Models.
Clevenger CV; Rui H
Endocrinology; 2022 Oct; 163(10):. PubMed ID: 35922139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
